Immunotherapy using chimeric antigen receptor (CAR)âengineered lymphocytes has shown impressive results in leukemia. However, for solid tumors such as colorectal cancer (CRC), new preclinical models are needed that allow to test CARâmediated cytotoxicity in a tissueâlike environment. Here, we developed a platform to study CAR cell cytotoxicity against 3âdimensional (3D) patientâderived colon organoids. Luciferaseâbased measurement served as a quantitative readâout for target cell viability. Additionally, we set up a confocal live imaging protocol to monitor effector cell recruitment and cytolytic activity at a single organoid level. As proof of principle, we demonstrated efficient targeting in diverse organoid models using CARâengineered NKâ92 cells directed toward a ubiquitous epithelial antigen (EPCAM). Tumor antigenâspecific cytotoxicity was studied with CARâNKâ92 cells targeting organoids expressing EGFRvIII, a neoantigen found in several cancers. Finally, we tested a novel CAR strategy targeting FRIZZLED receptors that show increased expression in a subgroup of CRC tumors. Here, comparative killing assays with normal organoids failed to show tumorâspecific activity. Taken together, we report a sensitive in vitro platform to evaluate CAR efficacy and tumor specificity in a personalized manner.